Holen Sie sich die Stockscreener-App
152.84
0.77%
-1.19
Handel nachbörslich:
153.58
0.74
+0.48%
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com
Novartis AG (ADR) Stock: Resilient Pharma Leader with Strong Fundamentals and Growth Potential for N - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG Stock: Resilient Pharma Leader with Strong Fundamentals and Strategic Growth Ahead for I - AD HOC NEWS
Novartis AG Stock Historical Valuations - GuruFocus
Novartis Bolsters Immunology Pipeline With Excellergy Deal - Zacks Investment Research
Dow Jones Top Company Headlines at 11 AM ET: Novartis to Buy Excellergy for Up to $2 Billion | Why ... - 富途牛牛
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy - Proactive Investors
Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline - Sahm
Novartis AG Stock: Strong Analyst Upgrades and Pipeline Momentum Drive Investor Interest in 2026 - AD HOC NEWS
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - ChartMill
Novartis AG (NVS) Bonds - gurufocus.com
Novartis AG stock gains 2% on SIX Swiss Exchange amid strong SMI performance and positive pharma sec - AD HOC NEWS
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock surges on Bank of America price target hike amid strong pharma pipeline momentum - AD HOC NEWS
Novartis AG Stock Faces Pressure Amid Multi-Billion Oncology Acquisition and Pipeline Advances - AD HOC NEWS
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 - ChartMill
Novartis AG Stock Gains Traction on Analyst Upgrades and Oncology Pipeline Momentum in 2026 - AD HOC NEWS
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis
Novartis AG stock dips on Swiss Exchange amid $3B breast cancer drug acquisition announcement - AD HOC NEWS
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - ChartMill
NVS Stock Quote Price and Forecast - CNN
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrades and Pipeline Momentum - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrade and Portfolio Shifts - ad-hoc-news.de
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Pharma Sector Shifts - AD HOC NEWS
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill
Novartis slides as shares trade ex-dividend for annual payout | NVS Stock News - Quiver Quantitative
Argus upgrades Novartis stock rating to buy on attractive entry point - investing.com
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Skeletal Dysplasia Market - GlobeNewswire Inc.
What's Driving the Market Sentiment Around Novartis AG? - Sahm
Novartis Stock: Can New Cancer Bets Keep Beating Big Pharma? - AD HOC NEWS
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Finviz
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) - Novartis
0.02%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):